Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of various hematologic malignancies. One of its rare and underrecognized adverse events is CAR T-cell-induced enterocolitis. We report a case of a 61-year-old man with multiple myeloma who developed chronic diarrhea 2 months after receiving B-cell maturation antigen (BCMA) directed CAR T-cell therapy. Duodenal and colonic biopsies revealed intraepithelial apoptotic bodies, which led to a diagnosis of CAR T-cell-induced enterocolitis. He was nonresponsive to high dose steroid. However, vedolizumab led to symptoms resolution. This case highlights the importance of recognizing CAR T-associated colitis and considering gut selective biologics such as vedolizumab in steroid-refractory disease.
No takes yet. Share an insight, caveat, or question.
Boonpiraks et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: